SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001387131-20-006203
Filing Date
2020-07-07
Accepted
2020-07-07 17:11:31
Documents
1
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES X, L.P.ATLAS VENTURE ASSOCIATES X, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM SC 13D repl-sc13da_070220.htm SC 13D/A 169893
  Complete submission text file 0001387131-20-006203.txt   171659
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

IRS No.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 500 UNICORN PARK WOBURN MA 01801
Business Address 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600
Replimune Group, Inc. (Subject) CIK: 0001737953 (see all company filings)

IRS No.: 822082553 | State of Incorp.: DE | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-90574 | Film No.: 201016630
SIC: 2836 Biological Products, (No Diagnostic Substances)